Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
Authors:
- Stephanie PepinSPStephanie Pepin
- Giancarlo IcardiGIGiancarlo Icardi
- The QHD00011 study teamTTThe QHD00011 study team
Open Access
- 29 October 2021
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (12) , 5475-5486
Abstract
A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65 y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64 y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalent influenza vaccine (IIV4-SD) in adults aged ≥60 y. This Phase III, randomized, modified double-blind, active-controlled study enrolled 1,528 participants aged ≥60 y, randomized 1:1 to a single injection of IIV4-HD or IIV4-SD. Hemagglutination inhibition (HAI) geometric mean titers (GMTs) were measured at baseline and D 28 and seroconversion assessed. Safety was described for 180 d after vaccination. The primary immunogenicity objective was superiority of IIV4-HD versus IIV4-SD, for all four influenza strains 28 d post vaccination in participants aged 60–64 and ≥65 y. IIV4-HD induced a superior immune response versus IIV4-SD in terms of GMTs in participants aged 60–64 y and those aged ≥65 y for all four influenza strains. IIV4-HD induced higher GMTs in those aged 60–64 y than those aged ≥65 y. Seroconversion rates were higher for IIV4-HD versus IIV4-SD in each age-group for all influenza strains. Both vaccines were well tolerated in participants ≥60 y of age, with no safety concerns identified. More solicited reactions were reported with IIV4-HD than with IIV4-SD. IIV4-HD provided superior immunogenicity versus IIV4-SD and was well tolerated in adults aged ≥60 y. IIV4-HD is assumed to offer improved protection against influenza compared with IIV4-SD in adults aged ≥60 y, as was previously assessed for adults aged ≥65 y.Keywords
Funding Information
- Sanofi Pasteur
This publication has 15 references indexed in Scilit:
- Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectivelyEurosurveillance, 2018
- Epidemiological and virological characteristics of influenza B: results of the Global Influenza B StudyInfluenza and Other Respiratory Viruses, 2015
- Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailtyVaccine, 2015
- Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older AdultsNew England Journal of Medicine, 2014
- Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)Eurosurveillance, 2014
- Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adultsVaccine, 2013
- Influenza Excess Mortality from 1950–2000 in Tropical SingaporePLOS ONE, 2009
- Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and OlderThe Journal of Infectious Diseases, 2009
- The Impact of Influenza Epidemics on HospitalizationsThe Journal of Infectious Diseases, 2000
- Two-sided confidence intervals for the single proportion: comparison of seven methodsStatistics in Medicine, 1998